Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (251-260 of 740) with videos related to

Pageof 74
Sort By:
Aging Cell|June 7, 2013
Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature agingEleni N Tsakiri, Gerasimos P Sykiotis, Issidora S Papassideri, et al.
American Journal of Hematology|January 9, 2025
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled TrialsIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaHeinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Haematologica|November 21, 2007
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myelomaMeletios A Dimopoulos, Vassilis L Souliotis, Athanasios Anagnostopoulos, et al.
Oncology|August 30, 2008
Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experienceChristos A Papadimitriou, Panagiotis Peitsidis, George Bozas, et al.
Leukemia & Lymphoma|October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trialMeletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Haematologica|April 5, 2015
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-pointMeletios A Dimopoulos, Maria T Petrucci, Robin Foà, et al.
Anticancer Research|March 14, 2007
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcomeEleni Efstathiou, Meletios A Dimopoulos, George Bozas, et al.
Haematologica|June 8, 2006
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acidMeletios A Dimopoulos, Efstathios Kastritis, Athanasios Anagnostopoulos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 16, 2006
Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysisAmanda Psyrri, Ziwei Yu, Aris Bamias, et al.
Pageof 74

Showing results (251-260 of 740) with videos related to

Sort By:
Pageof 74
Aging Cell|June 7, 2013
Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature agingEleni N Tsakiri, Gerasimos P Sykiotis, Issidora S Papassideri, et al.
American Journal of Hematology|January 9, 2025
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled TrialsIoannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, et al.
Blood Cancer Journal|February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaHeinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Haematologica|November 21, 2007
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myelomaMeletios A Dimopoulos, Vassilis L Souliotis, Athanasios Anagnostopoulos, et al.
Oncology|August 30, 2008
Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experienceChristos A Papadimitriou, Panagiotis Peitsidis, George Bozas, et al.
Leukemia & Lymphoma|October 23, 2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trialMeletios A Dimopoulos, Antonio Palumbo, Roman Hajek, et al.
Haematologica|April 5, 2015
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-pointMeletios A Dimopoulos, Maria T Petrucci, Robin Foà, et al.
Anticancer Research|March 14, 2007
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcomeEleni Efstathiou, Meletios A Dimopoulos, George Bozas, et al.
Haematologica|June 8, 2006
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acidMeletios A Dimopoulos, Efstathios Kastritis, Athanasios Anagnostopoulos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 16, 2006
Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysisAmanda Psyrri, Ziwei Yu, Aris Bamias, et al.
Pageof 74